Shire Plc - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 112 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Shire Plc - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Shire Plc - Product Pipeline Review - 2014', provides an overview of the Shire Plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Shire Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Shire Plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Shire Plc's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Shire Plc's pipeline products

Reasons to buy

- Evaluate Shire Plc's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Shire Plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Shire Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Shire Plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Shire Plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Shire Plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Shire Plc Snapshot 8
Shire Plc Overview 8
Key Information 8
Key Facts 8
Shire Plc - Research and Development Overview 9
Key Therapeutic Areas 9
Shire Plc - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Pipeline Products - Out-Licensed Products 17
Out-Licensed Products/Combination Treatment Modalities 18
Shire Plc - Pipeline Products Glance 19
Shire Plc - Late Stage Pipeline Products 19
Pre-Registration Products/Combination Treatment Modalities 19
Phase III Products/Combination Treatment Modalities 20
Shire Plc - Clinical Stage Pipeline Products 21
Phase II Products/Combination Treatment Modalities 21
Phase I Products/Combination Treatment Modalities 22
Shire Plc - Early Stage Pipeline Products 23
Preclinical Products/Combination Treatment Modalities 23
Discovery Products/Combination Treatment Modalities 24
Shire Plc - Unknown Stage Pipeline Products 25
Unknown Products/Combination Treatment Modalities 25
Shire Plc - Drug Profiles 26
anagrelide hydrochloride 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
guanfacine hydrochloride ER 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
icatibant acetate 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
velaglucerase alfa 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
C1 esterase inhibitor (human) 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
hydrocortisone MR 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
lifitegrast 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
lisdexamfetamine dimesylate 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
prucalopride succinate 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SHP-465 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
idursulfase 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
mecasermin rinfabate 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LUM-001 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
maribavir 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
SHP-610 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SHP-613 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
SSP-002358 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
VP-20621 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
PVS-10200 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SHP-611 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LUM-002 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SHP-622 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
HGT-3010 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SC-435 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecule to Inhibit A2A Receptor for CNS Disorders 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Antisense Oligonucleotide For Rare Genetic Disorders 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
etiguanfacine 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Shire Plc - Pipeline Analysis 69
Shire Plc - Pipeline Products by Target 69
Shire Plc - Pipeline Products by Route of Administration 71
Shire Plc - Pipeline Products by Molecule Type 72
Shire Plc - Pipeline Products by Mechanism of Action 73
Shire Plc - Recent Pipeline Updates 75
Shire Plc - Dormant Projects 96
Shire Plc - Discontinued Pipeline Products 99
Discontinued Pipeline Product Profiles 99
NRP-290 99
SPD-452 99
SPD-453 100
SPD-756 100
anagrelide hydrochloride 100
CX-516 100
HCV-796 100
HGT-1111 100
HGT-2610 100
lisdexamfetamine dimesylate 100
mesalamine ER 101
metoclopramide hydrochloride 101
ramatercept 101
SHP-557 101
SPD-427 101
SPD-491 101
SPD-554 101
SPD-556 102
valrocemide 102
Shire Plc - Company Statement 103
Shire Plc - Locations And Subsidiaries 104
Head Office 104
Other Locations & Subsidiaries 104
Shire Plc - Key Manufacturing Facilities 110
Appendix 111
Methodology 111
Coverage 111
Secondary Research 111
Primary Research 111
Expert Panel Validation 111
Contact Us 112
Disclaimer 112

List of Tables
Shire Plc, Key Information 8
Shire Plc, Key Facts 8
Shire Plc - Pipeline by Indication, 2014 11
Shire Plc - Pipeline by Stage of Development, 2014 13
Shire Plc - Monotherapy Products in Pipeline, 2014 14
Shire Plc - Partnered Products in Pipeline, 2014 15
Shire Plc - Partnered Products/ Combination Treatment Modalities, 2014 16
Shire Plc - Out-Licensed Products in Pipeline, 2014 17
Shire Plc - Out-Licensed Products/ Combination Treatment Modalities, 2014 18
Shire Plc - Pre-Registration, 2014 19
Shire Plc - Phase III, 2014 20
Shire Plc - Phase II, 2014 21
Shire Plc - Phase I, 2014 22
Shire Plc - Preclinical, 2014 23
Shire Plc - Discovery, 2014 24
Shire Plc - Unknown, 2014 25
Shire Plc - Pipeline by Target, 2014 70
Shire Plc - Pipeline by Route of Administration, 2014 71
Shire Plc - Pipeline by Molecule Type, 2014 72
Shire Plc - Pipeline Products by Mechanism of Action, 2014 74
Shire Plc - Recent Pipeline Updates, 2014 75
Shire Plc - Dormant Developmental Projects,2014 96
Shire Plc - Discontinued Pipeline Products, 2014 99
Shire Plc, Other Locations 104
Shire Plc, Subsidiaries 105
Shire Plc, Key Manufacturing Facilities 110